452 related articles for article (PubMed ID: 30077631)
1. Acute and long-term effects of zoledronate in adult patients with osteogenesis imperfecta. An observational Spanish study with five years of follow-up.
Pavón de Paz I; Rosado Sierra JA; Pérez Blanco C; Modroño Móstoles N; Guijarro de Armas G; Navea Aguilera C
Endocrinol Diabetes Nutr (Engl Ed); 2019 Feb; 66(2):108-116. PubMed ID: 30077631
[TBL] [Abstract][Full Text] [Related]
2. THE CLINICAL CHARACTERISTICS AND EFFICACY OF BISPHOSPHONATES IN AUDLT PATIENTS WITH OSTEOGENESIS IMPERGECTA.
Xu XJ; Ma DD; Lv F; Wang JY; Liu Y; Xia WB; Jiang Y; Wang O; Xing XP; Yu W; Li M
Endocr Pract; 2016 Nov; 22(11):1267-1276. PubMed ID: 27482615
[TBL] [Abstract][Full Text] [Related]
3. [Effects of zoledronic acid in adults with osteogenesis imperfecta].
Pavón de Paz I; Iglesias Bolaños P; Durán Martínez M; Olivar Roldán J; Guijarro De Armas G; Parra García JI
Endocrinol Nutr; 2010; 57(6):245-50. PubMed ID: 20510658
[TBL] [Abstract][Full Text] [Related]
4. Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists.
Bradbury LA; Barlow S; Geoghegan F; Hannon RA; Stuckey SL; Wass JA; Russell RG; Brown MA; Duncan EL
Osteoporos Int; 2012 Jan; 23(1):285-94. PubMed ID: 21739105
[TBL] [Abstract][Full Text] [Related]
5. EFFECTS OF LONG-TERM ALENDRONATE TREATMENT ON A LARGE SAMPLE OF PEDIATRIC PATIENTS WITH OSTEOGENESIS IMPERFECTA.
Lv F; Liu Y; Xu X; Wang J; Ma D; Jiang Y; Wang O; Xia W; Xing X; Yu W; Li M
Endocr Pract; 2016 Dec; 22(12):1369-1376. PubMed ID: 27482608
[TBL] [Abstract][Full Text] [Related]
6. Efficiency of Zoledronic Acid in Inhibiting Accelerated Periprosthetic Bone Loss After Cementless Total Hip Arthroplasty in Osteoporotic Patients: A Prospective, Cohort Study.
Fu GT; Lin LJ; Sheng PY; Li CC; Zhang JX; Shen J; Liu S; Xue YL; Lin SP; Wang K; Zheng QJ; Ding Y
Orthop Surg; 2019 Aug; 11(4):653-663. PubMed ID: 31456320
[TBL] [Abstract][Full Text] [Related]
7. Zoledronic acid in children with osteogenesis imperfecta and Bruck syndrome: a 2-year prospective observational study.
Otaify GA; Aglan MS; Ibrahim MM; Elnashar M; El Banna RA; Temtamy SA
Osteoporos Int; 2016 Jan; 27(1):81-92. PubMed ID: 26138583
[TBL] [Abstract][Full Text] [Related]
8. Zoledronic acid treatment in children with osteogenesis imperfecta.
Vuorimies I; Toiviainen-Salo S; Hero M; Mäkitie O
Horm Res Paediatr; 2011; 75(5):346-53. PubMed ID: 21293106
[TBL] [Abstract][Full Text] [Related]
9. Protocol of a randomised trial of teriparatide followed by zoledronic acid to reduce fracture risk in adults with osteogenesis imperfecta.
Hald JD; Keerie C; Weir CJ; Javaid MK; Lam W; Osborne P; Walsh J; Langdahl BL; Ralston SH
BMJ Open; 2023 Nov; 13(11):e078164. PubMed ID: 37993151
[TBL] [Abstract][Full Text] [Related]
10. ZOLEDRONIC ACID VERSUS ALENDRONATE IN THE TREATMENT OF CHILDREN WITH OSTEOGENESIS IMPERFECTA: A 2-YEAR CLINICAL STUDY.
Lv F; Liu Y; Xu X; Song Y; Li L; Jiang Y; Wang O; Xia W; Xing X
Endocr Pract; 2018 Feb; 24(2):179-188. PubMed ID: 29466057
[TBL] [Abstract][Full Text] [Related]
11. Relationship of Pathogenic Mutations and Responses to Zoledronic Acid in a Cohort of Osteogenesis Imperfecta Children.
Sun L; Hu J; Liu J; Zhang Q; Wang O; Jiang Y; Xia W; Xing X; Li M
J Clin Endocrinol Metab; 2022 Aug; 107(9):2571-2579. PubMed ID: 35727737
[TBL] [Abstract][Full Text] [Related]
12. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
Land C; Rauch F; Travers R; Glorieux FH
Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
[TBL] [Abstract][Full Text] [Related]
13. Fracture Prevention with Zoledronate in Older Women with Osteopenia.
Reid IR; Horne AM; Mihov B; Stewart A; Garratt E; Wong S; Wiessing KR; Bolland MJ; Bastin S; Gamble GD
N Engl J Med; 2018 Dec; 379(25):2407-2416. PubMed ID: 30575489
[TBL] [Abstract][Full Text] [Related]
14. Treatment with neridronate in children and adolescents with osteogenesis imperfecta: Data from open-label, not controlled, three-year Italian study.
Idolazzi L; Fassio A; Viapiana O; Rossini M; Adami G; Bertoldo F; Antoniazzi F; Gatti D
Bone; 2017 Oct; 103():144-149. PubMed ID: 28684193
[TBL] [Abstract][Full Text] [Related]
15. Duration of fracture prevention after zoledronate treatment in women with osteopenia: observational follow-up of a 6-year randomised controlled trial to 10 years.
Reid IR; Horne AM; Mihov B; Bava U; Stewart A; Gamble GD
Lancet Diabetes Endocrinol; 2024 Apr; 12(4):247-256. PubMed ID: 38452783
[TBL] [Abstract][Full Text] [Related]
16. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonate therapy for osteogenesis imperfecta.
Dwan K; Phillipi CA; Steiner RD; Basel D
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD005088. PubMed ID: 27760454
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Zoledronic Acid in children with Osteogenesis Imperfecta.
Riaz M; Hafeez S; Ibrahim MN; Khoso ZA; Laghari Br TM; Raza SJ
J Coll Physicians Surg Pak; 2022 Sep; 32(9):1165-1169. PubMed ID: 36089714
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonate therapy for osteogenesis imperfecta.
Dwan K; Phillipi CA; Steiner RD; Basel D
Cochrane Database Syst Rev; 2014 Jul; (7):CD005088. PubMed ID: 25054949
[TBL] [Abstract][Full Text] [Related]
20. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial.
Chevrel G; Schott AM; Fontanges E; Charrin JE; Lina-Granade G; Duboeuf F; Garnero P; Arlot M; Raynal C; Meunier PJ
J Bone Miner Res; 2006 Feb; 21(2):300-6. PubMed ID: 16418786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]